Skip to content
Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care episode artwork

EPISODE · Apr 20, 2022 · 17 MIN

Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care

from PeerVoice Clinical Pharmacology Video · host PeerVoice

Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care

Episode metadata supplied by the publisher feed · Published Apr 20, 2022

Embed this episode

Visit https://www.peervoice.com/ZDN860 to view the entire programme with slides. After completing “Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care”, participants will be able to: Discuss the latest guidance for treatment selection in relapsed/refractory multiple myeloma (RRMM); Evaluate the efficacy and safety data with anti-CD38 regimens for RRMM; Outline key factors that may guide anti-CD38–based treatment selection for patients with RRMM

Distinct summary based on available episode metadata or transcript content.

Ready to play

Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care

0:00 17:19

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of PeerVoice Clinical Pharmacology Video?

This episode is 17 minutes long.

When was this PeerVoice Clinical Pharmacology Video episode published?

This episode was published on April 20, 2022.

Can I download this PeerVoice Clinical Pharmacology Video episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!